|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-114.00/-0.97
|
企业价值
28.98M
|
资产负债 |
每股账面净值
7.06
|
现金流量 |
现金流量率
--
|
损益表 |
收益
1.92M
|
每股收益
16.40
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/04/28 07:49 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). |